Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas

被引:0
|
作者
Christensen, L
Simonsen, ACW
Heegaard, CW
Moestrup, SK
Andersen, JA
Andreasen, PA
机构
[1] UNIV AARHUS,DEPT BIOL MOLEC & STRUCT,DK-8000 AARHUS C,DENMARK
[2] GLOSTRUP CTY HOSP,DEPT PATHOL,GLOSTRUP,DENMARK
[3] STATE UNIV HOSP,DEPT PATHOL,COPENHAGEN,DENMARK
[4] UNIV AARHUS,DEPT BIOCHEM MED,DK-8200 AARHUS,DENMARK
[5] ODENSE UNIV HOSP,DEPT PATHOL,DK-5000 ODENSE,DENMARK
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the localization of urokinase-type plasminogen activator (u-PA), type-1 plasminogen-activator inhibitor (PAI-1), u-PA receptor (u-PAR) and alpha(2)-macroglobulin-receptor/low-density-lipoprotein- receptor-related protein (alpha(2)MR/LRP) in human breast tumors by immunohistochemical methods. Frozen sections of 133 primary breast carcinomas, 6 ductal carcinomas in situ and 33 lymph-node metastases were stained with monoclonal antibodies. Formalin-fixed sections of 15 primary tumors and 2 lymph-node metastases were stained with polyclonal antibodies. In primary tumors, u-PA and PAI-1 immunoreactivities were intense in macrophages and mast cells, and moderate in benign and malignant epithelial cells as well as in myofibroblasts and endothelial cells. A sub-group of poorly differentiated tumors showed particularly strong staining of stromal fibroblasts. u-PA immunoreactivity was also present in lymphocytes. alpha(2)MR/LRP and u-PAR immunoreactivities were intense in macrophages, but apart from these cells, alpha(2)MR/LRP was found only in fibroblasts, and u-PAR only in tumor cells located peripherally in tumor-cell clusters and glands and some myofibroblasts in the adjacent stroma. Lymphnode metastases showed staining for u-PA and PAI-1 both of cancer cells and of stromal fibroblasts, also staining for u-PA of lymphocytes. Similarly to some of the poorly differentiated primary tumors, approximately half of the metastases showed very strong staining of stromal fibroblasts, and extracts of these metastases had higher u-PA and PAI-1 levels, as determined by ELISA, than extracts of metastases without this staining pattern. alpha(2)MR/LRP was present only in fibroblasts and u-PAR only in some tumor cells. The presence of u-PA, PAI-1, alpha(2)MR/LRP and u-PAR was controlled biochemically by immunoblotting analyses, ligand-blotting analyses, and direct and reverse zymography. The spatial distribution and the variation in concentration of the various components of the plasminogen-activation system point to a complex, multifunctional role for the 4 proteins in and/or during the development and spread of breast cancer. (C) 1996 Wiley-Liss, Inc.
引用
收藏
页码:441 / 452
页数:12
相关论文
共 50 条
  • [1] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [2] A CELLULAR RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    BELIN, D
    BACCINO, D
    WOHLWEND, A
    ESTREICHER, A
    HUARTE, J
    VASSALLI, JD
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 46 - 46
  • [3] EXPRESSION AND LOCALIZATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR IN HUMAN GLIOMAS
    YAMAMOTO, M
    SAWAYA, R
    MOHANAM, S
    RAO, VH
    BRUNER, JM
    NICOLSON, GL
    RAO, JS
    CANCER RESEARCH, 1994, 54 (18) : 5016 - 5020
  • [4] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [5] Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
    Koji Sugioka
    Aya Kodama
    Koji Yoshida
    Kiyotaka Okada
    Masahiko Fukuda
    Yoshikazu Shimomura
    BMC Ophthalmology, 12
  • [6] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR TYPE-2 PLASMINOGEN-ACTIVATOR INHIBITOR COMPLEXES ARE NOT INTERNALIZED UPON BINDING TO THE UROKINASE-TYPE-PLASMINOGEN-ACTIVATOR RECEPTOR IN THP-1 CELLS - INTERACTION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR TYPE-2 PLASMINOGEN-ACTIVATOR INHIBITOR COMPLEXES WITH THE CELL-SURFACE
    RAGNO, P
    MONTUORI, N
    ROSSI, G
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 233 (02): : 514 - 519
  • [7] Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
    Sugioka, Koji
    Kodama, Aya
    Yoshida, Koji
    Okada, Kiyotaka
    Fukuda, Masahiko
    Shimomura, Yoshikazu
    BMC OPHTHALMOLOGY, 2012, 12
  • [8] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [9] IMMUNOHISTOCHEMICAL LOCALIZATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND INHIBITOR-2 IN EARLY HUMAN IMPLANTATION SITES
    HOFMANN, GE
    GLATSTEIN, I
    SCHATZ, F
    HELLER, D
    DELIGDISCH, L
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (02) : 671 - 676
  • [10] THE STRUCTURE OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR GENE
    CASEY, JR
    PETRANKA, JG
    KOTTRA, J
    FLEENOR, DE
    ROSSE, WF
    BLOOD, 1994, 84 (04) : 1151 - 1156